©1995 by The American Society for Biochemistry and Molecular Biology, Inc.
Truncation of the C-terminal Tail of the Follitropin Receptor Does Not Impair the Agonist- or Phorbol Ester-induced Receptor Phosphorylation and Uncoupling (*)

(Received for publication, July 13, 1995; and in revised form, August 16, 1995)

R. William Hipkin Xuebo Liu Mario Ascoli (§)

From the Department of Pharmacology, The University of Iowa College of Medicine, Iowa City, Iowa 52242-1109

ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
FOOTNOTES
ACKNOWLEDGEMENTS
REFERENCES

ABSTRACT

We have recently shown that addition of follitropin (FSH) or a phorbol ester (phorbol 12-myristate 13-acetate (PMA)) to cells expressing the recombinant follitropin receptor (FSHR) results in both phosphorylation and uncoupling of the FSHR from adenylyl cyclase. In the light of findings reported with other G protein-coupled receptors we have proposed that phosphorylation of the FSHR mediates the uncoupling from adenylyl cyclase. The experiments described herein represent the first attempt to determine the location of the amino acid residues that become phosphorylated in FSHR and to test the hypothesis that phosphorylation is responsible for uncoupling of FSHR from adenylyl cyclase.

As a first step in identifying which residues may be phosphorylated in response to hFSH and PMA, we constructed a mutant of the FSHR cDNA in which the C-terminal cytoplasmic tail was truncated at residue 635 (FSHR-t635), thus removing all but one of the potential phosphorylation sites present in the C-terminal tail. Cells expressing FSHR-t635 bind hFSH with the appropriate affinity and respond with increases in cAMP and inositol phosphate accumulation. The maximal cAMP and inositol phosphate responses of cells expressing FSHR-t635 are higher than those of cells expressing the wild type FSHR, but the concentration of hFSH required to elicit these responses is similar in both cell lines.

Immunoprecipitation of FSHR-t635 shows that the truncated receptor is still effectively phosphorylated in response to hFSH or PMA. Phosphoamino acid analysis reveals that, like the wild-type FSHR, FSHR-t635 phosphorylation occurs on serine and threonine residues. Peptide mapping suggests that the phosphorylated residues in the FSHR and FSHR-t635 are located within the same areas of the intracellular regions of the receptors. In addition to stimulating phosphorylation of FSHR-t635, hFSH and PMA also effectively uncouple the truncated receptor from adenylyl cyclase. Taken together, these data show that hFSH and PMA can both phosphorylate and uncouple a FSH receptor species with a cytoplasmic tail truncated at residue 635.


INTRODUCTION

When target cells are exposed to a hormone their responsiveness wanes with time, despite the continuous presence of hormone. This phenomenon, referred to as desensitization, is due to regulatory events that occur at the level of the hormone receptor as well as at postreceptor steps. While postreceptor events may be specific for the metabolic pathways that are activated in a given target cell, receptor events are more general in nature and conserved for a given family of receptors. There are at least two categories of regulatory events that occur at the level of the receptor and contribute to the process of desensitization. One of them, henceforth referred to as uncoupling, is defined as a change in the functional properties of a constant number of receptors resulting in a reduction in the ability of the receptor to activate its effector system. The other, henceforth referred to as down-regulation, is defined as a reduction in the density of cell surface receptors. Uncoupling is generally faster than down-regulation and is believed to be due to post-translational modifications of the receptor. Down-regulation, on the other hand, is slower and could be due to an increase in the rate of receptor sequestration/internalization or receptor degradation and/or a decrease in the rate of receptor externalization, processing, or synthesis.

It is now generally accepted that the phosphorylation of the beta(2)-adrenergic receptor that results as a consequence of agonist binding is an important event in the agonist-induced uncoupling of this receptor(1, 2, 3) . Although the phosphorylation of other G protein-coupled receptors (GPCRs) (^1)has not been studied in as much detail, it is rather clear that phosphorylation plays a central role in the regulation of the functions of many other GPCRs. Thus, in all other members of this family that have been studied so far, the removal or mutation of phosphorylation sites leads to a decrease in agonist-induced phosphorylation and an impairment in the process of agonist-induced uncoupling (see (4, 5, 6, 7, 8, 9, 10, 11) for a few examples).

The FSH-induced desensitization of the FSH-responsive adenylyl cyclase has been studied in some detail in target cells (Sertoli or granulosa cells) or membranes prepared therefrom(12, 13, 14, 15, 16, 17) . Moreover, since the agonist-induced desensitization of the isoproterenol-responsive adenylyl cyclase of rat Sertoli cells was also studied(15, 18) , it is relatively straightforward to compare the properties of the homologous desensitization induced by these two ligands in the same cell and to compare these data with what we know now about the mechanisms of desensitization of the beta(2)-adrenergic receptor. These studies showed that the time course, magnitude, and other biochemical properties of the agonist-induced desensitization of the FSH receptor (FSHR) and beta(2)-adrenergic receptor are very similar. Although in both cases one can demonstrate that uncoupling and down-regulation are involved in desensitization, uncoupling seems to be quantitatively more important than down-regulation(13, 19) . Last, in agreement with what was reported for the agonist-induced desensitization of beta(2)-adrenergic receptor in turkey erythrocyte membranes(20) , the FSH-induced desensitzation of FSHR in Sertoli cell membranes was reported to require Mg and ATP (15) .

Based on these findings, it is reasonable to propose that phosphorylation of the FSHR is responsible for the agonist-induced uncoupling of the FSHR. In fact, this hypothesis was initially proposed by Hansson and co-workers in a paper published 11 years ago(15) , but it has proven difficult to test until now. It is also reasonable to propose that the phosphorylation of the FSHR is involved in the heterologous regulation of the actions of FSHR. A particularly relevant example of this heterologous type of regulation of the actions of FSHR is that of agonists that activate the inositol phosphate/diacylgylcerol pathway (such as gonadotropin-releasing hormone in granulosa cells or purinergic agonists in Sertoli cells) or pharmacological agents (such as phorbol 12-myristate 13-acetate (PMA)) that activate protein kinase C(21, 22, 23) . In Sertoli or granulosa cells, the activation of this pathway results in an attenuation or desensitization of FSH actions, which seems to be due to a decrease in the functional properties (i.e. uncoupling) of the FSHR rather than to the down-regulation of the FSHR(21, 22, 23) .

Recent studies from this laboratory (24, 25, 26) have established a transfected cell system that (i) faithfully reproduces the process of FSH- or PMA-induced desensitization that has been documented in gonadal cells bearing the FSHR, (ii) allows for biochemical analyses of the phosphorylation of the FSHR, and (iii) can be used, in conjuction with site directed mutagenesis of the FSHR cDNA, to conclusively determine if FSHR phosphorylation is involved in the desensitization of FSHR. The experiments described herein represent the first attempt to determine the location of the amino acid residues that become phosphorylated in FSHR and to test the hypothesis that phosphorylation is responsible for uncoupling of FSHR from adenylyl cyclase.


EXPERIMENTAL PROCEDURES

A wild-type rat FSH receptor cDNA (27) was subcloned into the pcDNA1/Neo expression vector (Invitrogen, San Diego, CA). A cDNA encoding for the FSH receptor truncated at residue 635 (designated FSHR-t635) was constructed using the polymerase chain reaction (28) by introducing a stop codon after the codon for amino acid residue 635. The identity of this construct was verified by sequencing the entire open reading frame (29) The origin and handling of the parental human embryonic kidney cells (293 cells) and the methods used for transfection and isolation of clonal cell lines stably transfected with the wild type or mutant FSH receptor cDNAs have been described in detail elsewhere(11) . All transfected cells were maintained in Dulbecco's modified Eagle's medium supplemented with 10 mM HEPES, 10% new born calf serum, 50 µg/ml gentamicin, 700 µg/ml G418, pH 7.4, at 37 °C in a humidified atmosphere containing 5% CO(2). Experimental cultures were plated on day 0 and used on day 3 or 4.

Immunoprecipitation of the FSH Receptor from P-Labeled Cells

Metabolic labeling of cells and subsequent immunoprecipitation of the FSH receptor was achieved as described previously(24, 25) . Cells plated in 100-mm plates were labeled using 3.5 ml of phosphate-free Dulbecco's modified Eagle's medium containing 100-400 µCi/ml [P]orthophosphate for 3 h. All incubations were done at 37 °C under 5% CO(2). Unless otherwise stated in the figure legends, the various hormones and pharmacological agents were then added directly to the medium, and the cells were further incubated for the indicated times.

At the end of the incubation, the cells were scraped into ice-cold Buffer A (0.15 M NaCl, 20 mM Hepes, pH 7.4) containing various protease and phosphatase inhibitors (1 mM phenylmethylsulfonyl fluoride, 1 µM pepstatin A, 1 µM leupeptin, 5 mM EDTA, 3 mM EGTA, 50 mM beta-glycerophosphate, 10 mM sodium fluoride, 0.1 mM sodium orthovanadate, 100 nM okadaic acid, and 1 nM cypermethrin), pelleted by centrifugation, and lysed by vortexing in Buffer A containing 0.5% Nonidet P-40 and the aforementioned inhibitors. The detergent lysates were clarified by centrifugation at 100,000 times g for 30 min, and the protein content of the supernatants was assessed by the method of Bradford(30) . Equal amounts of lysate protein were then immunoprecipitated with a polyclonal antibody to the rat FSH receptor as described before(24, 25) . Immunoprecipitates were resolved on 7.5% sodium dodecyl sulfate-polyacrylamide gels in the presence of thiol-reducing agents as described previously(31) . Autoradiograms of the dried gels were obtained using intensifying screens, and the autoradiograms were scanned using a Bio-Rad Molecular Imaging System. All of the autoradiograms shown here are reproductions from the scanned images. Receptor phosphorylation was quantitated by densitometry using the software included with this imaging system.

Peptide Mapping

FSHR immunoprecipitated from P-labeled cells was detected by autoradiography of dried gels and excised. The dried gel piece was then rehydrated with water for 60 min, and the paper backing was removed. The receptor polypeptide within the gel slice was then chemically cleaved at tryptophan residues with N-chlorosuccinimide using a modification of the method described by Lischwe and Ochs (32) as follows. The receptor protein was first denatured by incubating the gel slices in 4 M guanidine hydrochloride in 80% acetic acid (33) for 20 min, with one change of denaturing solution. The gel slices were then incubated in the presence of 50 mMN-chlorosuccinimide in the same denaturing solution for 1-2 h, washed twice with 20 ml of water for 10 min each time, and equilibrated in 1.5 ml of Tricine gel sample buffer (12% glycerol (w/v), 4% sodium dodecyl sulfate (w/v), 2% mercaptoethanol (v/v), and 0.01% Bromphenol Blue (w/v) in 50 mM Tris-HCl, pH 6.8) for 90 min. This sample buffer was changed three times during the 90-min incubation.

The peptides within the gel slices were then separated using the discontinuous Tricine-urea SDS-polyacrylamide gel electrophoresis system described by Schägger and van Jagow (34) using a 16.5% acrylamide, 6 M urea resolving gel. Ultralow molecular mass standards ((34) ; 700-2500 daltons) (Sigma) were included in each experiment to determine the molecular weights of the generated peptides. Following electrophoresis, the Tricine gels were fixed by incubating them in 50% methanol, 10% acetic acid for 60 min followed by staining with 0.025% Bromphenol Blue in 10% acetic acid and destaining with 10% acetic acid. Autoradiograms of the wet gels were then obtained using intensifying screens.

FSH-induced Desensitization of the FSH-responsive Adenylyl Cyclase

Cells were plated in 35-mm wells that had been coated with a fibronectin-like engineered protein polymer (5 µg/ml) according to the manufacturer's instructions. Two to three days after plating, the cells were washed twice with 2-ml portions of warm assay medium (Waymouth MB 752/1 containing 1.12 g/liter NaHCO3, 50 µg/ml gentamicin, 20 mM HEPES, and 1 mg/ml bovine serum albumin, pH 7.4) and incubated at 37 °C in 1 ml of assay medium in the absence or presence of hFSH for various time periods. The free hormone was removed by placing the wells on ice and washing the cells three times with 2-ml portions of ice-cold Hanks' balanced salt solution containing 1 mg/ml bovine serum albumin. The receptor-bound hormone was then removed during a 4-min incubation with 2 ml of cold 100 mM NaCl, 50 mM glycine, pH 3, followed by a 2-ml wash with the same cold acid buffer(35) . Finally, the cells were washed twice with 2-ml portions of warm assay medium, and 1 ml of warm assay buffer was added to each well. The cells were then incubated in the presence or absence of various concentrations of hFSH for 15 min at 37 °C. At the end of this incubation the wells were placed on ice, the medium was aspirated, and the cells were washed once with a 2-ml aliquot of cold assay medium containing 0.5 mM isobutylmethylxanthine. The washing solution was removed, and the intracellular cAMP was extracted by adding 1 ml of 1 N perchloric acid containing 180 µg/ml theophylline. The samples were then processed, and the cAMP was assayed as described previously(35) .

FSH-induced Down-regulation of the FSHR

Cells were plated in coated dishes and treated as described above. Following a preincubation with or without hFSH for increasing periods of time at 37 °C, the free and receptor-bound hormones were removed as described above. The binding of I-FSH was then measured during an overnight incubation at 4 °C as described previously(24, 25) .

PMA-induced Desensitization of the FSH-responsive Adenylyl Cyclase

Cells (plated in 35-mm wells) were washed twice with 2-ml portions of assay medium. The cells were then incubated in 1 ml of assay medium containing 0.5 mM isobutylmethylxanthine for 15 min at 37 °C. PMA (200 nM) or vehicle was then added, and the incubation continued for 30 min. At this time, the cells were further incubated in the absence or presence of various concentrations of hFSH for 10 min. The samples were then processed and assayed for total cAMP (i.e. intracellular and extracellular) as described previously(11) .

Other Methods

The different parameters that describe the concentration-response curves were determined using the curve-fitting routine of the computer program Deltagraph and the equations initially described by DeLean et al.(36) . In the experiments measuring inositol phosphate accumulation, cells were metabolically labeled with [^3H]inositol in myo-inositol-free Dulbecco's modified Eagle's medium as described previously (11, 25) and incubated with various concentrations of hFSH or with 100 µM UTP for 60 min in the presence of 20 mM LiCl. The methods used for the measurement of phosphatidylinositols and inositol phosphate levels have also been described elsewhere(37) . Phosphoamino acid analysis was performed as described previously (38) except that the hydrolyzed phosphoamino acids were separated by two-dimensional thin layer electrophoresis(39) .

Hormones and Supplies

Purified hFSH (AFP-5720D) was kindly provided by the National Hormone and Pituitary Agency of the National Institute of Diabetes and Digestive and Kidney Diseases. [I]FSH was prepared as described previously (40) . Materials for cell culture, electrophoresis, Western blotting, and metabolic labeling were obtained as described elsewhere(24, 25) . The antibody to the FSH receptor has recently been described(24) . The fibronectin-like engineered polymer, PMA, leupeptin, pepstatin A, phenylmethylsulfonyl fluoride, N-chlorosuccinimide, and protein A-agarose were obtained from Sigma. Guanidine HCl was purchased from Mallincklrodt Chemical, Inc. (Paris, KY). Okadaic acid and cypermethrin were purchased from LC Laboratories (Woburn, MA). Phosphate- and myo-inositol-free Dulbecco's modified Eagle's medium were purchased from ICN Biomedicals (Irvine, CA), while [P]orthophosphate and [^3H]myo-inositol were obtained from DuPont NEN.


RESULTS

Preparation and Functional Properties of FSHR(t635)

We have previously established that addition of hFSH or PMA to stably transfected 293 cells expressing the FSHR results in an increase in FSH receptor phosphorylation(25) . However, in these initial experiments, pharmacological concentrations of the hFSH (EC = 500 ng/ml) were required to increase receptor phosphorylation during a 15-min incubation. As it is highly unlikely that such high concentrations of FSH occur in vivo, we attempted to improve the sensitivity of our assay by increasing the length of the incubation with FSH to 1 h by using subconfluent cell cultures and by omitting the lectin purification step that was used prior to receptor immunoprecipitation (25) . As shown in Fig. 1, these changes have now allowed us to detect an increase in FSHR phosphorylation with 3 ng/ml hFSH, a half-maximal increase with about 30 ng/ml hFSH, and a maximal increase with 100 ng/ml hFSH. While the maximal increase in receptor phosphorylation detected under these conditions is similar to that detected previously(25) , the FSH concentration range that elicits receptor phosphorylation is now similar to the concentration range required to detect FSH-induced increases in cAMP, estradiol, or c-fos mRNA levels in Sertoli cells (41, 42, 43) as well as FSH-induced increases in cAMP accumulation in mammalian or insect cells transfected with the FSHR(25, 44) . The reported EC values for these responses vary between 2 and 30 ng/ml, and maximal responses are attained at 100-500 ng/ml hFSH.


Figure 1: Effect of increasing concentrations of hFSH on the phosphorylation of FSHR in 293F(wt-10) cells. P(i)-labeled 293F(wt-10) cells were incubated with the indicated concentrations of hFSH for 1 h at 37 °C. The P-labeled FSHR was then immunoprecipitated with AntiF and resolved on SDS gels as described under ``Experimental Procedures.'' The top panel shows a scan of the relevant portion of the autoradiogram, and the bottom panel shows the densitometric quantitation of the data. The results of a representative experiment are presented.



Since truncations of the C-terminal tails of several G protein-coupled receptors have provided useful information about the location and functions of their phosphorylation sites(4, 5, 7, 11, 45) , we constructed a mutant of the FSHR cDNA in which the C-terminal cytoplasmic tail was truncated at residue 635 (designated FSHR-t635). As shown in Fig. 2, this truncation removes all but one of the potential phosphorylation sites (serine and threonine residues; see (25) ) present in the C-terminal cytoplasmic tail of the FSHR. The possible phosphorylation of the remaining cytoplasmic tail serine cannot be examined by C-terminal truncation of the receptor because truncations done upstream of residue 635 generally result in mutant receptors that do not localize to the cell surface (data not shown).


Figure 2: Intracellular regions of the rat FSHR. The three cytoplasmic loops and the C-terminal cytoplasmic tail of the rat FSHR are shown(27) . Amino acid residues enclosed in squares are identical in the rat FSHR and the rat LHR (53) All potential phosphorylation sites (i.e. serine/threonine residues) are marked as being part of a consensus sequence for protein kinase C (arrows) or as not being part of any known consensus sequence (shaded squares or circles). The location of the truncation used in these studies (t635) is also indicated.



Clonal, stably transfected cell lines expressing FSHR-t635 were prepared and matched with a clonal cell line stably transfected with the FSHR-wt expressing equivalent numbers of cell surface receptors. (Table 1). Quantitation of the FSH receptors expressed in these cell lines by immunoprecipitation of the FSHR from S-labeled cells or by immunoblotting support the conclusion that 293F(wt-10) and 293F(t635-5) cells express equivalent numbers of the mature 74-kDa FSHR (data not shown).



The cAMP and inositol phosphate responses of 293F(wt-10) and 293F(t635-5) cells to FSH are shown in Fig. 3. The maximal responses of 293F(t635-5) cells to FSH are 2-3-fold higher than those of 293F(wt-10) cells, but there are no differences in the EC values for these responses between the two cells lines. The EC values for cAMP and inositol phosphate accumulation in both cell lines are 2-5 ng/ml and 150-250 ng/ml hFSH, respectively. Since the cAMP response to cholera toxin and the inositol phosphate response to UTP are similar for these two cell lines (Fig. 3), it can be safely concluded that the increased efficacy of hFSH in the 293F(t635-5) cells is not due to clonal variation.


Figure 3: Effects of increasing concentrations of FSH on cAMP and inositol phosphate accumulation in 293F(wt-10) and 293F(t635-5) cells. Top panel, cells were preincubated with 0.5 mM methylisobutylxanthine for 15 min and then incubated with the indicated concentrations of hFSH for 15 min or with 500 ng/ml cholera toxin for 2 h. Total (i.e. intracellular + extracellular) cAMP levels were then measured using a radioimmunoassay as described under ``Experimental Procedures.'' Each point represents the mean ± S.E. of three independent experiments. Basal levels of cAMP were 6.2 ± 1.3 and 11.2 ± 0.3 for 293F(wt-10) and 293F(t635-5) cells, respectively. Bottom panel, cells that had been prelabeled with [^3H]inositol were incubated with the indicated concentrations of hFSH or UTP in the presence of 20 mM LiCl for 60 min. The medium was removed, and total inositol phosphates and phosphatidylinositols were measured as described under ``Experimental Procedures.'' The amount of inositol phosphates detected are presented as a percentage of the sum of the phosphatidylinositol + inositol phosphates detected. Each point represents the mean ± S.E. of three independent experiments. Basal levels of inositol phosphates were 3.7 ± 0.7 and 4.2 ± 1.0 for 293F(wt-10) and 293F(t635-5) cells, respectively.



Phosphorylation of FSHR-wt and FSHR-t635

Immunoprecipitation of the FSHR from P-labeled 293F(wt-10) and 293F(t635-5) cells revealed that FSH and PMA each markedly increased phosphorylation of both the full-length and the truncated FSHR. (Fig. 4). In addition, the magnitude of the FSH- or PMA-induced phosphorylation of FSHR-t635 was equivalent to that of FSHR-wt, suggesting that none of the 12 serines and threonines located downstream of residue 635 in the C-terminal cytoplasmic tail are phosphorylated in response to FSH or PMA. It is also important to note that although the mass of FSHR-t635 is expected to decrease by about 5 kDa, the resolution of our polyacrylamide gels is such that it does not resolve this small difference in mass. This phenomenon was also noted in analogous studies with several C-terminal truncations of the LHR (11) .


Figure 4: Effects of hFSH or PMA on the phosphorylation of FSHR-wt or FSHR-t635-5. P(i)-labeled cells were incubated with no additions, 1000 ng/ml hFSH, or 200 nM PMA for 15 min. Cell lysates were prepared, and identical amounts of lysate were immunoprecipitated with AntiF and resolved on SDS gels as described under ``Experimental Procedures.'' The data presented are from a representative experiment showing the scanned image of the relevant portion of the autoradiogram.



Another interpretation of the finding that FSHR-t635 is phosphorylated to about the same extent as FSHR-wt is that truncation of the cytoplasmic tail of FSHR may artifactually expose new phosphorylation site(s) that are not accessible for phosphorylation in the full-length FSH receptor. In order to assess this possibility, two additional experiments were performed. In one experiment, we compared the phosphoamino acid analysis of FSHR-wt and FSHR-t635. Since we have previously shown that FSHR-wt is phosphorylated on serine and threonine residues upon FSH or PMA stimulation(25) , we reasoned that if phosphorylation of FSHR-t635 were occurring at different sites, it would be possible for the phosphoamino acid analysis of FSHR-t635 to be different from that of FSHR-wt. Both receptor species were found to be phosphorylated in serine and threonine residues, however (data not shown). To more stringently analyze potential differences in phosphorylation sites between these two receptor species, we generated peptide maps of FSHR-wt and FSHR-t635 phosphorylated in response to FSH or PMA. Peptide maps were obtained by chemical cleavage of the immunoprecipitated receptor with N-chlorosuccinimide, a reagent that cleaves polypeptides at tryptophan residues(32, 33) . Fig. 5shows that the phosphopeptide maps generated upon cleavage of the full-length or truncated FSH receptor isolated from FSH-stimulated cells are indistinguishable from each other. In addition, the phosphopeptide maps of the full-length and truncated FSHR isolated from PMA-stimulated cells were also the same, and were very similar to those obtained from FSH-stimulated cells (data not shown).


Figure 5: Phosphopeptide maps of FSHR-wt and FSHR-t635. The P-labeled FSHR-wt or FSHR-t635 was isolated from pre-labeled cells that had been stimulated with 1000 ng/ml hFSH for 15 min at 37 °C. Cell lysates were prepared, immunoprecipitated with AntiF, and resolved on SDS gels as described under ``Experimental Procedures.'' The relevant portion of the gels was cut, digested with N-chlorosuccinimide, and subjected to electrophoresis on Tricine-urea-SDS gels as described under ``Experimental Procedures.'' The results (densitometric scan of an autoradiogram) of a representative experiment are shown. The apparent molecular weights shown were calculated based on the migration of molecular weight standards.



Taken together, these data suggest that the residues that become phosphorylated in FSHR-wt or FSHR-t635 are located within the same areas of the intracellular regions of the receptor. Therefore, removal of the terminal 40 amino acids of the cytoplasmic tail of the FSHR does not remove serine or threonine residues that are phosphorylated in response to the ligand or to PMA, nor does it artifactually introduce additional phosphorylation sites.

Desensitization of FSHR-wt and FSHR-t635

By analogy with what is known about other G protein-coupled receptors, we have previously proposed that phosphorylation of the FSHR is responsible for the uncoupling of the FSHR from adenylyl cyclase that is observed when cells are incubated with FSH or PMA(25) . Having established that the truncated FSH receptor expressed in the 293F(t635-5) cells is phosphorylated in response to FSH or PMA, we next assessed whether incubation with either of these stimuli would uncouple the truncated receptor species from adenylyl cyclase.

The results summarized in Fig. 6(left panel) show that preincubation of 293F(wt-10) or 293F(t635-5) cells with hFSH results in a decrease in the cAMP response of these cells to a further stimulation with hFSH. Importantly, the data in Fig. 6also show that the time course and magnitude of this phenomenon are very similar in both cell lines. Under these experimental conditions, however, the blunting of FSH-stimulated cAMP accumulation following preincubation with FSH could result from reduced numbers of cell surface receptors (receptor down-regulation) or from receptor uncoupling. To quantitate the contribution of these two pathways to the blunting of the cAMP response, we also measured the extent of FSH-induced FSHR down-regulation in cells incubated under identical conditions. As can be seen in the right panel of Fig. 6, the extent of FSHR down-regulation is similar in both cell lines, and the magnitude of down-regulation is rather small compared with the magnitude of the loss of cAMP responsiveness. For example, a 15-min preincubation with hFSH reduced I-FSH binding to only 91 ± 2% and 87 ± 3% of control levels in 293F(wt-10) and 293F(t635-5) cells, respectively. In contrast, under the same conditions, hFSH-stimulated cAMP accumulation was reduced to 60 ± 7% and 55 ± 2% of control levels in 293F(wt-10) and 293F(t635-5) cells, respectively. Therefore, the FSH-induced blunting of the FSH-sensitive adenylyl cyclase appears to be due primarily to to FSHR uncoupling rather than down-regulation.


Figure 6: Time course of hFSH-induced desensitization and down-regulation. Left panel, cells were preincubated with 100 ng/ml hFSH at 37 °C for the times indicated. The free and receptor-bound hormones were then removed by washing at neutral and acid pH as described under ``Experimental Procedures,'' and the cells were divided into two groups and incubated with or without 100 ng/ml hFSH for 15 min at 37 °C. At the end of this incubation the medium was removed, and the intracellular cAMP was measured. The amount of cAMP present in the cells incubated without hFSH was then subtracted from that present in the cells incubated with hFSH. Finally, this response was then expressed as the percentage of the response of cells treated in an identical fashion but preincubated for the same length of time without hFSH. Each point represents the mean ± S.E. of three independent experiments. Right panel, cells were preincubated with 100 ng/ml hFSH at 37 °C for the times indicated. The free and receptor-bound hormones were then removed by washing at neutral and acid pH, respectively, as described under ``Experimental Procedures.'' Residual FSH receptors were then measured during an overnight incubation at 4 °C in the presence of 100 ng/ml I-hFSH as described under ``Experimental Procedures.'' Results are expressed as the percentage of the I-hFSH binding detected in cells preincubated for the same length of time, but without hFSH. Each point represents the mean ± S.E. of three independent experiments.



In additional experiments, we showed that preincubation of 293F(wt-10) or 293F(t635-5) cells with hFSH induced a similar reduction in maximal FSH-stimulated cAMP accumulation between the two cell lines, (40 and 54%, respectively) but had no effect on the concentration of hFSH required to elicit a half-maximal response (Fig. 7).


Figure 7: Cyclic AMP responses of 293F(wt-10) or 293F(t635-5) cells preincubated with hFSH. Cells were preincubated with or without 100 ng/ml hFSH for 30 min at 37 °C as indicated. The free and receptor-bound hormones were then removed by washing at neutral and acid pH, respectively, as described under ``Experimental Procedures,'' and the cells were incubated with buffer only or with the indicated concentrations of hFSH for 15 min at 37 °C. At the end of this incubation, the medium was removed and the intracellular cAMP was measured. The amount of cAMP present in the cells incubated with buffer only was then subtracted from that present in the cells incubated with the increasing concentrations of hFSH. Each point represents the mean of two independent experiments. The bars extend to the individual values obtained in each experiment.



Last, the data summarized in Fig. 8show that preincubation of 293F(wt-10) or 293F(t635-5) cells with PMA effectively reduces the FSH-stimulated cAMP accumulation. In both cell lines, the blunting of FSH-stimulated cAMP accumulation by PMA was particularly evident with low stimulatory concentrations of FSH. In fact, a preincubation with PMA either had no effect or enhanced the stimulatory effects of high concentrations of FSH on cAMP accumulation ( Fig. 8and (25) ). This stimulatory effect of PMA, however, is not specific for the FSH receptor, as it can also be detected when cAMP synthesis is activated with any concentration of cholera toxin (25) .


Figure 8: Effect of PMA on the FSH responses of 293F(wt-10) or 293F(t635-5) cells. Cells were preincubated for 15 min at 37 °C with 0.5 mM methylisobutylxanthine. PMA (200 nM) or vehicle was then added, and the incubation was continued for another 30 min at 37 °C. At the end of this incubation the cells received buffer only or the indicated concentrations of hFSH, and the incubation was continued for an additional 15 min at 37 °C. Total cAMP (i.e. intracellular + extracellular) was measured as described under ``Experimental Procedures.'' Each bar represents the mean ± S.E. of three independent experiments. The numbers above each pair of bars depict the response of the cells treated with PMA expressed as the percentage of the response of the cells treated without PMA.



Taken together, these data show that hFSH or PMA can both phosphorylate and uncouple a FSH receptor species with a cytoplasmic tail truncated at residue 635.


DISCUSSION

We have previously shown that the recombinant FSH receptor expressed in mammalian cells becomes phosphorylated on serine and threonine residues when cells are exposed to FSH or PMA(25) . The experiments presented herein were designed as an initial attempt to identify the location of the phosphorylated residues and to test the hypothesis that phosphorylation is responsible for the uncoupling of FSHR from adenylyl cyclase.

Since 13 of the 25 serine/threonine residues present in the intracellular regions of the FSHR are located in the C-terminal tail (Fig. 2), a mutant FSHR cDNA with a truncated C-terminal cytoplasmic tail was constructed. This mutant cDNA encodes for a protein (designated FSHR-t635) in which 12 of the 25 intracellular serine/threonine residues were removed. The analysis of more severe truncations was not possible due to the lack of expression of those truncated receptors at the cell surface. FSHR-t635 is fully functional, in that cells expressing this truncated receptor species bind hFSH with high affinity (Table 1) and respond to the bound hormone with the expected increases in cAMP and inositol phosphate accumulation (Fig. 3). In fact, while the potency of hFSH is similar in cells expressing FSHR-wt or FSHR-t635, the efficacy of hFSH is 2-3-fold higher in cells expressing FSHR-t635 (Fig. 3). These results are similar to those reported for several C-terminal truncations of the closely related LHR (11, 46) .

FSHR-t635 appears to be phosphorylated normally in response to FSH or PMA stimulation (Fig. 4). The simplest interpretation of these results is that the 12 serine/threonine residues removed in this truncated receptor are not phosphate acceptors. Another more complex interpretation is that the truncation of the C-terminal cytoplasmic tail resulted in the exposure of phosphorylation sites that are not accessible in the full-length receptor. In this scenario, FSHR-wt and FSHR-t635 would be phosphorylated to the same extent but on different sites. The detection of phosphoserine and phosphothreonine residues in the full-length and truncated receptors as well as the similarity of the phosphopeptide maps generated when either receptor is cleaved with N-chlorosuccinimide (Fig. 5), however, strongly suggest that FSHR-wt and FSHR-t635 are phosphorylated in the same sites.

The finding that FSHR-t635 is phosphorylated normally in response to FSH stimulation is interesting because C-terminal truncations of many other GPCRs(4, 5, 7, 45) , including the closely related LHR(11) , have been previously shown to abolish (or at least drastically diminish) agonist-induced phosphorylation. In fact, to the best of our knowledge, there are only two other GPCRs that become phosphorylated upon agonist stimulation, in which the phosphorylated residues are not localized in the C-terminal tail. These are the human m2 muscarinic receptor(47) , where the phosphorylation sites appear to be located in the third intracellular loop, and the human alpha2-adrenergic receptor, where the phosphorylation sites cannot be located in the C-terminal tail simply because this receptor does not have any serine/threonine residues in its C-terminal tail(48, 49) . Based on the amino acid sequence of the rat FSHR(27) , it can be predicted that N-chlorosuccinimide cleavage should generate three phosphopeptides: a 22-kDa peptide containing the third intracellular loop and the C-terminal cytoplasmic tail, a 7.4-kDa peptide containing the first intracellular loop, and a 2.96-kDa peptide containing the second intracellular loop. As shown in Fig. 5, however, there are at least four detectable peptides that are generated upon N-chlorosuccinimide cleavage, and their molecular weights do not correspond to the predicted molecular weights of the three theoretical peptides. These findings could be reconciled by assuming that the cleavage conditions used may not be optimal and by the knowledge that there is a fair amount of uncertainty in the molecular weight estimates derived from the separation system used (34) . Thus, it is possible that the 18- and 8.8-kDa peptides shown in Fig. 7correspond to the 22- and 7.4-kDa peptides predicted above, and the 14.4- and 12-kDa peptides may be incomplete degradation products. If this interpretation is correct, the data presented in Fig. 5suggests that phosphorylation occurs in the first and third intracellular loops. Clearly, however, additional studies utilizing peptide mapping and/or site-directed mutagenesis will be needed to provide a definitive identification of the phosphorylation sites.

The finding that truncation of the C-terminal tail of the FSHR does not affect the agonist- or PMA-induced uncoupling (Fig. 6Fig. 7Fig. 8) is in agreement with our hypothesis that phosphorylation is responsible for uncoupling. Admittedly, however, these results do not provide a rigorous test for our hypothesis, and additional experiments will be needed to conclusively determine if this hypothesis is correct. The main functional difference between FSHR-t635 and FSHR-wt is that the former is a better transducer of at least two FSH-induced signals: cAMP and inositol phosphate generation. Thus, while the concentrations of hFSH required to elicit half-maximal responses are similar in 293F(wt-10) and 293F(t635-5) cells, the maximal cAMP and inositol phosphate responses are higher in 293F(t635-5) cells (Fig. 3). At first glance these results may appear contradictory to the finding that the FSH-induced uncoupling of FSHR-t635 is normal because the increased responsiveness could be due to a loss of desensitization. Another interpretation that accommodates both sets of results, however, is that the C-terminal tail of the FSHR contains sequences that restrain the interaction of this receptor with G proteins. Thus, when these sequences are removed a more productive interaction takes place, and hormonal responsiveness is enhanced even if desensitization is normal. Enhanced hormonal responsiveness upon truncation of the C-terminal tail of GPCRs is, in fact, a rather common finding(4, 9, 11, 50, 51, 52) , which does not always correlate with an impairment of desensitization. The best example of this lack of correlation is the closely related LHR, where truncations at residues 653 and 631 result in an enhanced human CG responsiveness but phosphorylation and desensitization are impaired only in LHR(t631) and not in LHR(t653) ((11) ). (^2)

Last, it is interesting to note that the removal of the C-terminal tail of the FSHR did not affect either the agonist or the PMA-induced phosphorylation (Fig. 4) and that the phosphoamino acid analysis (not shown) and peptide maps of the FSHR phosphorylated in response to FSH or PMA (not shown) are very similar. Thus, it appears that regardless of the stimulus used (i.e. FSH or PMA), the FSHR becomes phosphorylated on serine/threonine residues present in one or more of the three cytoplasmic loops and/or in Ser, the only potential phosphorylation site that remains in the C-terminal tail of FSHR-t635 (c.f. Fig. 2). These findings also suggest that at least some of the serine/threonine residues phosphorylated in response to either stimuli are the same. While this conclusion also remains to be confirmed, it is interesting to note that in the closely related LHR, the PMA- or agonist-induced phosphorylation maps to the same four serine residues in the C-terminal tail(11) . In contrast to the similarities in the phosphoamino acid analysis and phosphopeptide maps of the FSHR isolated from cells stimulated with PMA or FSH, there is a rather obvious difference in the effects of FSH or PMA on the desensitization of the FSHR. A preincubation of cells with FSH leads to a reduction in the FSH-induced cAMP accumulation at all concentrations of FSH tested (Fig. 7), while a preincubation of cells with PMA leads to a reduction in the FSH-induced cAMP accumulation only at low concentrations of FSH (Fig. 8). This and other differences between the functional effects of PMA and FSH (25) suggest that the sites phosphorylated in response to PMA stimulation are not identical to those phosphorylated in response to FSH stimulation. This suggestion is also supported by the finding that protein kinase C is only partially responsible for mediating the FSH-induced phosphorylation of the FSHR (25) .

In summary, then, the data presented herein have eliminated 12 of the 25 serine/threonine residues present in the FSHR as potential phosphorylation sites of agonist- or PMA-induced phosphorylation and as mediators of agonist- or PMA-induced uncoupling of FSHR from adenylyl cyclase. Additional studies will be needed to determine the location of the phosphorylation sites, to determine if the same sites are phosphorylated in response to FSH- or PMA-stimulation, and to ascertain the functional impact of phosphorylation on the functions of FSHR.


FOOTNOTES

*
This work was supported by National Institutes of Health (NIH) Grant HD-28962 and by the Roy J. Carver Charitable Trust. The services and facilities provided by the Diabetes and Endocrinology Research Center of the University of Iowa (supported by NIH Grant DK25295) are also gratefully acknowledged. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore by hereby marked ``advertisement'' in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

§
To whom correspondence should be addressed: Dr. Mario Ascoli, Dept. of Pharmacology, University of Iowa, 2-512 BSB, Iowa City, IA 52242-1109. Tel.: 319-335-9907; Fax: 319-335-9925; mario-ascoli@uiowa.edu.

(^1)
The abbreviations used are: GPCR, G protein-coupled receptors; FSH, follitropin; hFSH, human FSH; FSHR, FSH receptor; PMA, phorbol 12-myristate 13-acetate; LH, luteinizing hormone; LHR, LH receptor.

(^2)
Z. Wang, R. W. Hipkin, and M. Ascoli, unpublished observations.


ACKNOWLEDGEMENTS

We thank Cheri B. Whisler and Kari Kruel for expert technical assistance and Dr. Deborah L. Segaloff for reading the manuscript.


REFERENCES

  1. Hausdorff, W. P., Caron, M. G., and Lefkowitz, R. J. (1990) FASEB J. 4, 2881-2889 [Abstract]
  2. Lefkowitz, R. J., Hausdorff, W. P., and Caron, M. G. (1990) Trends Pharmacol. Sci. 11, 190-194 [CrossRef][Medline] [Order article via Infotrieve]
  3. Inglese, J., Freedman, N. J., Koch, W. J., and Lefkowitz, R. J. (1993) J. Biol. Chem. 268, 23735-23738 [Free Full Text]
  4. Lattion, A.-L., Diviani, D., and Cotecchia, S. (1994) J. Biol. Chem. 269, 22887-22893 [Abstract/Free Full Text]
  5. Ishii, K., Chen, J., Ishii, M., Koch, W. J., Freedman, N. J., Lefkowitz, R. J., and Coughlin, S. R. (1994) J. Biol. Chem. 269, 1125-1130 [Abstract/Free Full Text]
  6. Bennett, N., and Sitaramayya, A. (1988) Biochemistry 27, 1710-1715 [Medline] [Order article via Infotrieve]
  7. Takano, T., Honda, Z., Sakanaka, C., Izumi, T., Kameyama, K., Haga, K., Haga, T., Kurokawa, K., and Shimizu, T. (1994) J. Biol. Chem. 269, 22453-22458 [Abstract/Free Full Text]
  8. Prossnitz, E. R., Kim, C. M., Benovic, J. L., and Ye, R. D. (1994) J. Biol. Chem. 270, 1130-1137 [Abstract/Free Full Text]
  9. Alblas, J., van Etten, I., Khanum, A., and Moolenaar, W. H. (1995) J. Biol. Chem. 270, 8944-8951 [Abstract/Free Full Text]
  10. Sánchez-Yagüe, J., Rodríguez, M. C., Segaloff, D. L., and Ascoli, M. (1992) J. Biol. Chem. 267, 7217-7220 [Abstract/Free Full Text]
  11. Hipkin, R. W., Wang, Z., and Ascoli, M. (1995) Mol. Endocrinol. 9, 151-158 [Abstract]
  12. Jahnsen, T., Gordeladze, J. O., Torjesen, P. A., and Hansson, V. (1980) Arch. Androl. 5, 169-177 [Medline] [Order article via Infotrieve]
  13. Le Gac, F., Attramadal, H., Jahnsen, T., and Hansson, V. (1985) Biol. Reprod. 32, 916-924 [Abstract]
  14. Jahnsen, T., Verhoeven, G., Purvis, K., Cusan, L., and Hansson, V. (1982) Arch. Androl. 8, 205-211 [Medline] [Order article via Infotrieve]
  15. Attramadal, H., Jahnsen, T., and Hansson, V. (1984) Mol. Cell. Endocrinol. 34, 221-228 [Medline] [Order article via Infotrieve]
  16. Johanson, C., Nordenström, K., and Hamberger, L. (1989) Hum. Reprod. (Oxf.) 4, 629-635 [Abstract]
  17. Woody, C. J., and LaBarbera, A. R. (1989) Endocrinology 124, 2261-2267 [Abstract]
  18. Attramadal, H., Eikvar, L., and Hansson, V. (1988) Endocrinology 123, 1060-1068 [Abstract]
  19. Attramadal, H., Le Gac, F., Jahnsen, T., and Hansson, V. (1984) Mol. Cell. Endocrinol. 34, 1-6 [CrossRef][Medline] [Order article via Infotrieve]
  20. Nambi, P., Sibley, D. R., Stadel, J. M., Michel, T., Peters, J. R., and Lefkowitz, R. J. (1984) J. Biol. Chem. 259, 4629-4633 [Abstract/Free Full Text]
  21. Kasson, B. G., Conn, P. M., and Hsueh, A. J. W. (1985) Mol. Cell. Endocrinol. 42, 29-37 [Medline] [Order article via Infotrieve]
  22. Filippini, A., Riccioli, P., De Cesaris, P., Paniccia, R., Teti, A., Stefanini, M., Conti, M., and Ziparo, E. (1994) Endocrinology 134, 1537-1545 [Abstract]
  23. Monaco, L., and Conti, M. (1987) Mol. Cell. Endocrinol. 49, 227-236 [CrossRef][Medline] [Order article via Infotrieve]
  24. Quintana, J., Hipkin, R. W., and Ascoli, M. (1993) Endocrinology 133, 2098-2104 [Abstract]
  25. Quintana, J., Hipkin, R. W., Sánchez-Yagüe, J., and Ascoli, M. (1994) J. Biol. Chem. 269, 8772-8779 [Abstract/Free Full Text]
  26. Sánchez-Yagüe, J., Hipkin, R. W., and Ascoli, M. (1993) Endocrinology 132, 1007-1016 [Abstract]
  27. Sprengel, R., Braun, T., Nikolics, K., Segaloff, D. L., and Seeburg, P. H. (1990) Mol. Endocrinol. 4, 525-530 [Abstract]
  28. Ho, S. N., Hunt, H. D., Horton, R. M., Pullen, J. K., and Pease, L. R. (1989) Gene (Amst.) 77, 51-59 [CrossRef][Medline] [Order article via Infotrieve]
  29. Sanger, F., Nicklen, S., and Coulson, A. R. (1977) Proc. Natl. Acad. Sci. U. S. A. 74, 5463-5467 [Abstract]
  30. Bradford, M. M. (1976) Anal. Biochem. 53, 304-308
  31. Kim, I.-C., Ascoli, M., and Segaloff, D. L. (1987) J. Biol. Chem. 262, 470-477 [Abstract/Free Full Text]
  32. Lischwe, M. A., and Ochs, D. (1982) Anal. Biochem. 127, 453-457 [Medline] [Order article via Infotrieve]
  33. Mahoney, W. C., and Hermodson, M. A. (1979) Biochemistry 18, 3810-3814 [Medline] [Order article via Infotrieve]
  34. Schägger, H., and von Jagow, G. (1987) Anal. Biochem. 166, 368-379 [Medline] [Order article via Infotrieve]
  35. Segaloff, D. L., and Ascoli, M. (1981) J. Biol. Chem. 256, 11420-11423 [Abstract/Free Full Text]
  36. De Lean, A., Munson, P. J., and Rodbard, D. (1978) Am. J. Physiol. 235, E97-E102
  37. Ascoli, M., Pignataro, O. P., and Segaloff, D. L. (1989) J. Biol. Chem. 264, 6674-6681 [Abstract/Free Full Text]
  38. Hoelscher, S. R., and Ascoli, M. (1993) Endocrinology 132, 2229-2238 [Abstract]
  39. Cooper, J. A., Sefton, B. M., and Hunter, T. (1983) Methods Enzymol. 99, 387-402 [Medline] [Order article via Infotrieve]
  40. Ascoli, M., and Puett, D. (1978) Proc. Natl. Acad. Sci. U. S. A. 75, 99-102 [Abstract]
  41. Hall, S. H., Joseph, D. R., French, F. S., and Conti, M. (1988) Mol. Endocrinol. 2, 55-61 [Abstract]
  42. Monaco, L., Adamo, S., and Conti, M. (1988) Endocrinology 123, 2032-2039 [Abstract]
  43. Fletcher, P. W., and Reichert, L. E., Jr. (1984) Mol. Cell. Endocrinol. 34, 39-49 [CrossRef][Medline] [Order article via Infotrieve]
  44. Liu, X., DePasquale, J. A., Griswold, M. D., and Dias, J. A. (1994) Endocrinology 135, 682-691 [Abstract]
  45. Bouvier, M., Hausdorff, W. P., De Blasi, A., O'Dowd, B. F., Kobilka, B. K., Caron, M. G., and Lefkowitz, R. J. (1988) Nature 333, 370-373 [CrossRef][Medline] [Order article via Infotrieve]
  46. Rodríguez, M. C., Xie, Y.-B., Wang, H., Collison, K., and Segaloff, D. L. (1992) Mol. Endocrinol. 6, 327-336 [Abstract]
  47. Richardson, R. M., Kim, C., Benovic, J. L., and Hosey, M. M. (1993) J. Biol. Chem. 268, 13650-13656 [Abstract/Free Full Text]
  48. Kobilka, B. K., Matsui, H., Kobilka, T. S., Yang-Feng, T. L., Francke, U., Caron, M. G., Lefkowitz, R. J., and Regan, J. W. (1987) Science 238, 650-656 [Medline] [Order article via Infotrieve]
  49. Benovic, J. L., Regan, J. W., Matsui, H., Mayor, F., Jr., Cotecchia, S., Leeb-Lundberg, L. M. F., Caron, M. G., and Lefkowitz, R. J. (1987) J. Biol. Chem. 262, 17251-17253 [Abstract/Free Full Text]
  50. Parker, E. M., and Ross, E. M. (1991) J. Biol. Chem. 266, 9987-9996 [Abstract/Free Full Text]
  51. Thomas, W. G., Thekkumkara, T. J., Motel, T. J., and Baker, K. M. (1995) J. Biol. Chem. 270, 207-213 [Abstract/Free Full Text]
  52. Matus-Leibovitch, N., Nussenzveig, D. R., Gershengorn, M. C., and Oron, Y. (1995) J. Biol. Chem. 270, 1041-1047 [Abstract/Free Full Text]
  53. Segaloff, D. L., and Ascoli, M. (1993) Endocrine Rev. 14, 324-347 [Abstract]

©1995 by The American Society for Biochemistry and Molecular Biology, Inc.